(AVTR) Avantor - Ratings and Ratios
Materials, Consumables, Equipment, Services
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 45.3% |
| Value at Risk 5%th | 62.0% |
| Relative Tail Risk | -16.80% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.83 |
| Alpha | -62.50 |
| CAGR/Max DD | -0.32 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.438 |
| Beta | 1.140 |
| Beta Downside | 1.011 |
| Drawdowns 3y | |
|---|---|
| Max DD | 61.62% |
| Mean DD | 25.44% |
| Median DD | 18.84% |
Description: AVTR Avantor January 06, 2026
Avantor, Inc. (NYSE:AVTR) supplies mission-critical products and services across biopharma, healthcare, education, government, advanced-technology, and applied-materials markets worldwide, operating in the Americas, Europe, Asia, the Middle East, and Africa.
The company’s catalog includes high-purity chemicals and reagents, lab consumables, formulated silicone materials, custom excipients, single-use assemblies, chromatography resins and columns, analytical sample-prep kits, microbiology products, clinical-trial kits, and fluid-handling tips.
In addition to consumables, Avantor offers equipment such as filtration and virus-inactivation systems, incubators, analytical instruments, ultra-low-temperature freezers, biosafety cabinets, peristaltic pumps, and related critical-environment supplies, plus on-site services ranging from lab and production support to procurement, scale-up, and biopharmaceutical development.
Key metrics (as of FY 2023) show revenue of roughly $13.5 billion, a 9 % YoY growth rate driven largely by expanding demand for single-use bioprocessing solutions and the resurgence of vaccine manufacturing, and an adjusted EBITDA margin near 15 %. The life-sciences tools sector benefits from a projected 8 % CAGR through 2028, underpinned by rising biologics pipelines, tighter regulatory scrutiny on contamination control, and sustained government spending on health-security infrastructure.
For a deeper, data-driven assessment of Avantor’s valuation dynamics, you might find ValueRay’s analytical platform worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: -82.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -1.33 > 1.0 |
| NWC/Revenue: 11.27% < 20% (prev 12.83%; Δ -1.56% < -1%) |
| CFO/TA 0.06 > 3% & CFO 644.4m > Net Income -82.2m |
| Net Debt (3.61b) to EBITDA (644.6m): 5.59 < 3 |
| Current Ratio: 1.49 > 1.5 & < 3 |
| Outstanding Shares: last quarter (681.7m) vs 12m ago -0.19% < -2% |
| Gross Margin: 33.13% > 18% (prev 0.34%; Δ 3280 % > 0.5%) |
| Asset Turnover: 53.64% > 50% (prev 53.11%; Δ 0.53% > 0%) |
| Interest Coverage Ratio: 1.36 > 6 (EBITDA TTM 644.6m / Interest Expense TTM 174.7m) |
Altman Z'' (< 1.1 .. > 2.6) 1.96
| A: 0.06 (Total Current Assets 2.26b - Total Current Liabilities 1.52b) / Total Assets 11.68b |
| B: 0.14 (Retained Earnings 1.62b / Total Assets 11.68b) |
| C: 0.02 (EBIT TTM 236.8m / Avg Total Assets 12.26b) |
| D: 0.91 (Book Value of Equity 5.57b / Total Liabilities 6.11b) |
| Altman-Z'' Score: 1.96 = BBB |
ValueRay F-Score (Strict, 0-100) 35.71
| 1. Piotroski: 4.50pt |
| 2. FCF Yield: 4.40% |
| 3. FCF Margin: 7.96% |
| 4. Debt/Equity: 0.69 |
| 5. Debt/Ebitda: 5.59 |
| 6. ROIC - WACC: -5.24% |
| 7. RoE: -1.38% |
| 8. Revenue Trend: -93.01% |
| 9. EPS Trend: -79.74% |
What is the price of AVTR shares?
Over the past week, the price has changed by -1.37%, over one month by +8.63%, over three months by -21.73% and over the past year by -43.91%.
Is AVTR a buy, sell or hold?
- Strong Buy: 6
- Buy: 4
- Hold: 11
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the AVTR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13 | 6.8% |
| Analysts Target Price | 13 | 6.8% |
| ValueRay Target Price | 9.9 | -19.3% |
AVTR Fundamental Data Overview January 19, 2026
P/S = 1.2609
P/B = 1.4884
Revenue TTM = 6.58b USD
EBIT TTM = 236.8m USD
EBITDA TTM = 644.6m USD
Long Term Debt = 3.64b USD (from longTermDebt, last quarter)
Short Term Debt = 219.8m USD (from shortTermDebt, last quarter)
Debt = 3.86b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.61b USD (from netDebt column, last quarter)
Enterprise Value = 11.90b USD (8.29b + Debt 3.86b - CCE 251.9m)
Interest Coverage Ratio = 1.36 (Ebit TTM 236.8m / Interest Expense TTM 174.7m)
EV/FCF = 22.72x (Enterprise Value 11.90b / FCF TTM 523.6m)
FCF Yield = 4.40% (FCF TTM 523.6m / Enterprise Value 11.90b)
FCF Margin = 7.96% (FCF TTM 523.6m / Revenue TTM 6.58b)
Net Margin = -1.25% (Net Income TTM -82.2m / Revenue TTM 6.58b)
Gross Margin = 33.13% ((Revenue TTM 6.58b - Cost of Revenue TTM 4.40b) / Revenue TTM)
Gross Margin QoQ = 32.42% (prev 32.92%)
Tobins Q-Ratio = 1.02 (Enterprise Value 11.90b / Total Assets 11.68b)
Interest Expense / Debt = 1.15% (Interest Expense 44.2m / Debt 3.86b)
Taxrate = 16.68% (142.4m / 853.9m)
NOPAT = 197.3m (EBIT 236.8m * (1 - 16.68%))
Current Ratio = 1.49 (Total Current Assets 2.26b / Total Current Liabilities 1.52b)
Debt / Equity = 0.69 (Debt 3.86b / totalStockholderEquity, last quarter 5.57b)
Debt / EBITDA = 5.59 (Net Debt 3.61b / EBITDA 644.6m)
Debt / FCF = 6.89 (Net Debt 3.61b / FCF TTM 523.6m)
Total Stockholder Equity = 5.98b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.67% (Net Income -82.2m / Total Assets 11.68b)
RoE = -1.38% (Net Income TTM -82.2m / Total Stockholder Equity 5.98b)
RoCE = 2.46% (EBIT 236.8m / Capital Employed (Equity 5.98b + L.T.Debt 3.64b))
RoIC = 1.96% (NOPAT 197.3m / Invested Capital 10.04b)
WACC = 7.21% (E(8.29b)/V(12.15b) * Re(10.12%) + D(3.86b)/V(12.15b) * Rd(1.15%) * (1-Tc(0.17)))
Discount Rate = 10.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.18%
[DCF Debug] Terminal Value 79.89% ; FCFF base≈613.0m ; Y1≈562.2m ; Y5≈500.8m
Fair Price DCF = 10.21 (EV 10.57b - Net Debt 3.61b = Equity 6.96b / Shares 681.8m; r=7.21% [WACC]; 5y FCF grow -10.37% → 2.90% )
EPS Correlation: -79.74 | EPS CAGR: -52.18% | SUE: -4.0 | # QB: 0
Revenue Correlation: -93.01 | Revenue CAGR: -4.20% | SUE: -1.36 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.20 | Chg30d=-0.003 | Revisions Net=+0 | Analysts=15
EPS next Year (2026-12-31): EPS=0.91 | Chg30d=+0.001 | Revisions Net=+1 | Growth EPS=+1.2% | Growth Revenue=-0.0%
Additional Sources for AVTR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle